A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Clinical trial NCT06284317 · RECRUITING
Trial details
- NCT number
- NCT06284317
- Sponsor
- ETOP IBCSG Partners Foundation
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-15
- Primary completion
- 2029-10-01
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.